Hemostemix Announces the Second Stem Cell Recipient Interview: One Week to No Chest Pain October 4, 2021
Insights into China’s Pharmaceutical Industry Trends from a 2,000-strong Industry Conference September 30, 2021 Life Science
Hemostemix Announces Closing of First Tranche of Unit Private Placement September 21, 2021 Life Science
Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years September 14, 2021 Life Science
Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results July 6, 2021 Life Science
HempFusion Launches Private Label Business Division, Awarded 10 SKU Private Label Deal with Leading National Retailer June 3, 2021 Life Science
Hemostemix Announces that, Due to the COVID-19 Pandemic, the Annual and Special Meeting Will Only Be Held via Zoom and Shareholders are Requested to Follow the Meeting Instructions Mailed to the Shareholders of Record May 31, 2021 Life Science
Hemostemix Announces the TSX Venture’s Preliminary Approval of the Closing of a $2,500,000 Convertible Debenture at $0.40 per Unit and Corporate Update May 29, 2021 Life Science
